

November 8, 2022  
SymBio Pharmaceuticals Limited  
Fuminori Yoshida  
Representative Director  
President and Chief Executive Officer  
(Securities Code: 4582)

### Revision to Earnings Forecast for FY 2022

TOKYO, Japan, November 8, 2022 -- SymBio Pharmaceuticals Limited (Headquarters: Tokyo, "SymBio" or the "Company") today announced that the Company's Board of Directors today approved the following revision to the earnings forecast for fiscal year ending December 31, 2022. The earnings forecast was previously announced on August 4, 2022. The revision reflects the Company's current performance trends and outlook.

#### 1. Revision to Earnings Forecast for FY 2022 (January 1, 2022 to December 31, 2022)

	Net Sales	Operating Profit	Ordinary Profit	Profit attributable to owners of parent	Earnings per share
	Yen millions	Yen millions	Yen millions	Yen millions	Yen
Forecast (A)	10,003	1,770	1,750	1,480	38.35
Actual (B)	10,003	2,000	2,300	1,650	42.42
Difference (B-A)	—	230	550	170	—
Percentage Change (%)	—	13.0	31.4	11.5	—
[Reference] Prior Year Results (FY 2021)	—	—	—	—	—

\*The Company's results for the previous fiscal year were on a non-consolidated basis.

	Net Sales	Operating Profit	Ordinary Profit	Net Profit	Earnings per share
	Yen millions	Yen millions	Yen millions	Yen millions	Yen
[Reference] Prior Year Results (FY 2021)	8,256	1,016	1,001	2,032	53.04

#### 2. Reasons for changes

Net Sales of 10,003 million yen (+21.2% year over year) is unchanged compared to the forecast of August 4, 2022. Operating profit is expected to be 2,000 million yen (+96.9% year on year), an increase of 230 million yen compared to the 1,770 million yen announced on August 4, 2022, primarily due to reduced

SG&A expense while the Company continues to prioritize global development of BCV. Ordinary profit is expected to be 2,300 million yen (+129.7% year on year), an increase of 550 million yen from the 1,750 million yen announced on August 4, 2022. The increase in ordinary profit is primarily due to foreign exchange gains on foreign currency assets. Profit attributable to owners of parent has also increased to 1,650 million yen, an increase of 170 million yen from the 1,480 million yen announced on August 4, 2022.

\*Earnings forecasts, financial projections, and other forecasts or forward looking statements contained in this disclosure have been prepared by the Company at its discretion and based on information available to the Company as of the date of this disclosure. Actual results may vary materially from the information contained in this disclosure as a result of changes to business, economic, financial, or other assumptions and conditions.

**[Contact]**

Investor Relations

Tel: +81(0)3 5472 1125